Guillem Laporta
Analyst @ Andera Partners
Paris, France
Guillem Laporta is a Series A investor at Andera Partners in Paris focused on Fertility and Health Care. Guillem is responsible for identifying and evaluating investment opportunities from the scientific and business perspectives. He will also represent Ysios at the board of directors of its portfolio companies.Guillem has over 7 years’ experience in Venture Capital. Prior to joining Ysios, Guillem worked at Edmond de Rothschild Group in Paris (nowAndera Partners). There, he was involved in the execution of several investments in Europe and United States. These included opportunities in the domain of neurodegeneration, oncology, cardiovascular pathologies, and respiratory diseases. He previously worked at Caixa Capital Risc, where he was part of the life sciences team.Guillem is a CFA charter holder and holds a bachelor’s degree in Biotechnology from the Universitat Autonoma de Barcelona and a bachelor’s degree in Business Administration from the Universitat Pompeu Fabra.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Guillem Laporta invests in
Stages Guillem Laporta invests in
Countries Guillem Laporta invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Fertility 1 (33%)
- Health Care 1 (33%)
- Life Science 1 (33%)
- Therapeutics 1 (33%)
- Biotechnology 1 (33%)
Stage
- Series A 1 (33%)
- Series B 1 (33%)
Country
- Switzerland 1 (33%)
- The Netherlands 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ReproNovo
|
ReproNovo is providing patients all over the world with significant improvement by developing cutting-edge therapeutic solutions for uterine disorders including adenomyosis and for male and female infertility. | $65M / Series A / May 21, 2025 | |
VarmX
|
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $37M / Series B / May 25, 2023 | |
|
VarmX
|
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $36.3M / Series B / Jul 08, 2020 |
Co-Investors
About Andera Partners
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Andera Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
François Boudreault
Censor
|
|||
Francois Xavier Mauron
Partner
|
|||
Gilles Nobecourt
Partner
|
|||
|
Guillem Laporta
Analyst
|
|||
Jan Van den Bossche
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Guillem Laporta invest in?
Guillem Laporta invests primarily in Fertility, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Guillem Laporta?
Public channels for Guillem Laporta include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Guillem Laporta last invest?
The most recent investment recorded for Guillem Laporta closed in May 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
